Neuberger Berman Group LLC lowered its holdings in Sanofi (NYSE:SNY) by 10.4% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 97,994 shares of the company’s stock after selling 11,318 shares during the period. Neuberger Berman Group LLC’s holdings in Sanofi were worth $4,695,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in SNY. Fisher Asset Management LLC raised its holdings in shares of Sanofi by 8.1% in the 2nd quarter. Fisher Asset Management LLC now owns 13,638,458 shares of the company’s stock valued at $653,419,000 after acquiring an additional 1,022,953 shares in the last quarter. Global Financial Private Capital LLC purchased a new stake in shares of Sanofi in the 1st quarter valued at about $35,034,000. Bank of America Corp DE raised its holdings in shares of Sanofi by 8.2% in the 1st quarter. Bank of America Corp DE now owns 7,531,334 shares of the company’s stock valued at $340,792,000 after acquiring an additional 572,652 shares in the last quarter. Parametric Portfolio Associates LLC raised its holdings in shares of Sanofi by 25.3% in the 1st quarter. Parametric Portfolio Associates LLC now owns 1,460,280 shares of the company’s stock valued at $66,078,000 after acquiring an additional 295,242 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. purchased a new stake in shares of Sanofi in the 1st quarter valued at about $7,619,000. 9.33% of the stock is currently owned by hedge funds and other institutional investors.
A number of brokerages recently weighed in on SNY. Argus reissued a “buy” rating and set a $55.00 price objective on shares of Sanofi in a report on Friday, September 1st. HSBC Holdings plc raised Sanofi from a “reduce” rating to a “hold” rating in a report on Wednesday, August 30th. BidaskClub raised Sanofi from a “sell” rating to a “hold” rating in a report on Saturday, August 5th. Cowen and Company reissued a “market perform” rating and set a $52.00 price objective (up from $46.00) on shares of Sanofi in a report on Tuesday, August 1st. Finally, Zacks Investment Research raised Sanofi from a “hold” rating to a “buy” rating and set a $55.00 price objective on the stock in a report on Friday, June 2nd. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $54.00.
In other news, major shareholder Sanofi purchased 60,595 shares of the company’s stock in a transaction that occurred on Wednesday, August 23rd. The stock was bought at an average cost of $478.98 per share, with a total value of $29,023,793.10. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.00% of the stock is currently owned by corporate insiders.
Sanofi (NYSE SNY) opened at 48.83 on Wednesday. The stock has a market capitalization of $122.64 billion, a PE ratio of 11.63 and a beta of 0.88. The firm has a 50-day moving average price of $48.23 and a 200-day moving average price of $47.22. Sanofi has a 52 week low of $36.81 and a 52 week high of $50.24.
Sanofi (NYSE:SNY) last announced its quarterly earnings results on Monday, July 31st. The company reported $0.74 EPS for the quarter, meeting analysts’ consensus estimates of $0.74. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The company had revenue of $8.66 billion during the quarter, compared to analyst estimates of $8.71 billion. Sanofi’s revenue was down 2.3% on a year-over-year basis. Equities research analysts predict that Sanofi will post $3.34 EPS for the current fiscal year.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.